Form 8-K · Current Report · Filed 2026-02-17
Halozyme Therapeutics Reports Record Revenue and Reiterates 2026 Financial Guidance
Halozyme Therapeutics, Inc. reported record total revenue of $1.4 billion for the full year 2025, driven by growth in its ENHANZE drug delivery technology. The company also expanded its drug delivery portfolio with the acquisitions of Elektrofi's Hypercon technology and Surf Bio's hyperconcentration technology. Halozyme is reiterating its 2026 financial guidance, expecting total revenue between $1.710 billion and $1.810 billion, with adjusted EBITDA between $1.125 billion and $1.205 billion, and non-GAAP diluted EPS between $7.75 and $8.25.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-26-000023
- CIK
- 0001159036
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$79.44
Next session
-7.8%
Since filing
+38.8%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.